Reader Comment on “Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris”

Abstract

Get full access to this article

View all access options for this article.

References

Kushner

CJ.

Wang

Tovanabutra

et al. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404.doi:10.1001/jamadermatol.2019.3236

31642878

Wang

H-H.

Liu

C-W.

Y-C.

Huang

Y-C

. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928-932.doi:10.2340/00015555-2116

25881672

Amber

KT.

Hertl

. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29(4):777-782.doi:10.1111/jdv.12678

25185723

Joly

Maho-Vaillant

Prost-Squarcioni

et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.doi:10.1016/S0140-6736(17)30070-3

28342637

Mignard

Maho-Vaillant

Golinski

M-L

et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(5):545-552.doi:10.1001/jamadermatol.2020.0290

32186656